The APAC Pyrogen Testing Market size was worth USD 148.56 million in 2022 and is estimated to be growing at a CAGR of 16.7% to reach USD 321.55 million by 2027.
The growing number of biologic products and increased research and development emphasis is predicted to drive the Asia Pacific pyrogen testing market. Also, the rise in response to fast-developing pharmaceutical and biotechnology manufacturing and an increasing number of new therapy promotions are majorly fuelling the pyrogen testing market growth in the APAC region.
An increase in manufacturing companies and the government’s investments in research and development for new product development is another major factor contributing to the market growth. Moreover, the manufacturers in the region are focusing on the introduction of and development of products that provide lucrative opportunities for the market players.
In addition, the key players in the region are implementing various strategies to gain a competitive advantage over the marketplace. The strategies include mergers, acquisitions, and partnerships to maintain their dominance and increase their revenue share in the division. On the other hand, the pyrogen testing market is predicted to increase significantly with many biological products.
Furthermore, growing government assistance and introducing new medications are also boosting the pyrogen testing market growth. This has also contributed to the large-scale development of therapeutically improved pharmaceuticals, forcing producers to improve productivity, cost efficiency, and variations. As a result, companies are implementing good manufacturing practices through biological testing at various stages of the production cycle, adding to the market’s growth.
The market's growth is expected to be hampered by the strict regulatory policies, ambiguous reimbursement concerns, and a lack of understanding regarding the modern testing processes.
This research report on the Asia-Pacific pyrogen testing market has been segmented and sub-segmented into the following categories:
By Test Type:
Geographically, the Asia Pacific is expected to be the fastest developing regional market globally, owing to the constantly growing population and rising healthcare expenditure. However, the APAC market is anticipated to account for a significant share in the global market during the forecast period. Many pharmaceutical companies concentrate on Asian countries like China and India on drug development, growth, and production. Clinical trials are now being contributed by clinical research organizations in the Asia Pacific region. The availability of less stringent government rules for drug production, a giant gene pool, and fast-increasing healthcare infrastructure are primary elements driving the sector’s expansion in this field. Clinical trial groups are concentrating their efforts in Asian countries. The countries such as China, India, South Korea, Japan, Australia, and the rest of Asia Pacific are expanding the APAC Asian pyrogen testing market.
The Chinese pyrogen testing market is expected to account substantial share in the APAC market during the forecast period due to its large population, A Nation Reimbursement Drug List (NRDL), in February 2017, including about 340 new drugs. In addition, there are around 800 novel compounds in the pipeline among the local biotech firms based in China, with 70-80 in phase III.
The Indian pyrogen testing market is one of the fastest-growing countries in the region. The market growth is supported by rising disposable income, improving the healthcare sector, and favorable reimbursement policies. In addition, India has been taking substantial steps to promote itself as the world’s leading central biopharmaceutical innovation hub, including fostering Public-Private Partnerships (PPPs) in biopharmaceutical research and development projects.
The South Korean pyrogen testing market is likewise working to establish itself as a worldwide biotech center, focusing on biosimilars, vaccine development, and stem cell therapies. In addition, the growing need for rehabilitative treatments for life-threatening diseases like cancer and diabetes underscores the necessity for medication research and development, and thus the demand for pyrogen testing kits for effective quality testing and management.
KEY MARKET PLAYERS:
Companies playing a promising role in the APAC pyrogen testing market profiled in this report are Associates of Cape Cod, Inc., Lonza Group, Merck Kgaa, Thermo Fisher Scientific, Ellab A/S, Genscript, Hyglos GmbH, Charles River Laboratories, Inc., Wako Chemicals USA, Inc., and WUXI Pharmatech (Cayman) Inc.